Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. heart attack
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Heart Attack Articles & Analysis

90 news found

Lead Poisoning Awareness Campaign for Adults Launched by New York State Department of Health

Lead Poisoning Awareness Campaign for Adults Launched by New York State Department of Health

“Some of the health effects listed by the department due to lead exposure include decreased brain and kidney function, raised blood pressure, increased chances of having a heart attack or stroke, and for pregnant individuals, increased chances of a miscarriage and harm to a baby’s development before birth,” said Frank Selamie, President of CTSI. ...

ByCochrane & Associates, LLC


Creative Enzymes Unveils Semaglutide, a Promising Solution for Comprehensive Diabetes Management

Creative Enzymes Unveils Semaglutide, a Promising Solution for Comprehensive Diabetes Management

Furthermore, Semaglutide has demonstrated the ability to reduce the risk of cardiovascular events, such as heart attacks and strokes, in individuals with type 2 diabetes and established cardiovascular disease. ...

ByCreative Enzymes


CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation

CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation

Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments, over heart attacks and strokes, to age-related degeneration. "Whilst Mitochondria have been known as disease targets for a long time, treating them has proven challenging", notes Dr. ...

Bycellvie Inc.


Revacept protects during carotid artery surgery

Revacept protects during carotid artery surgery

Revacept proved to be particularly effective when stroke, bleeding and heart attack were considered together. Here, the novel active ingredient in the dosage of 120 milligrams caused a significant reduction of more than 54 percent compared to those treated with placebo. ...

ByadvanceCOR GmbH


XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

The company also plans other clinical studies in additional cardiovascular indications, including heart failure caused by ischemic heart disease and as adjunctive therapy to percutaneous coronary intervention. ...

ByXyloCor Therapeutics


World Diabetes Day

World Diabetes Day

If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye disease, kidney disease and nerve damage. ...

ByNeurovalens Limited


Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

” The product labels of all JAK inhibitors will be updated to include a precautionary approach for patients aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past and those at increased risk of cancer. ...

ByGalapagos NV


Elucid’s Next-Generation Plaque Analysis and FFRCT Technology to be Featured on 2022 AHA Scientific Sessions Program

Elucid’s Next-Generation Plaque Analysis and FFRCT Technology to be Featured on 2022 AHA Scientific Sessions Program

Elucid has developed FDA-cleared Plaque Analysis and investigational FFRCT tools designed to enable physicians to diagnose and understand the direct cause of myocardial ischemia, while also identifying coronary plaque that is at highest risk to rupture and result in a heart attack. “Elucid has developed a plaque analysis software based on ground truth ...

ByElucid


Elucid Appoints Dr. Michael Lesh to Board of Directors

Elucid Appoints Dr. Michael Lesh to Board of Directors

Advanced clinical insights from Elucid equip physicians with critical information designed to enable precision medicine for both assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke, as well as assessing blockages to determine the need for revascularization. ...

ByElucid


World Sepsis Day – Raising awareness about one of the most prevalent and deadly, yet misdiagnosed, medical conditions.

World Sepsis Day – Raising awareness about one of the most prevalent and deadly, yet misdiagnosed, medical conditions.

Robert Hancock at The University of British Columbia, is raising awareness about sepsis: a serious medical condition that is the body’s overwhelming and life-threatening response to infection that can lead to tissue damage, organ failure, and death. It more common than heart attack and claims more lives than any cancer but is often misdiagnosed. ...

BySepset Biosciences Inc.


CDRD Launches New Company Developing Life-Saving Sepsis Diagnostic

CDRD Launches New Company Developing Life-Saving Sepsis Diagnostic

The company is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis – a global healthcare problem that is more common than heart attack and claims more lives than any cancer. Infectious disease testing (including sepsis) is one of the fastest growing molecular diagnostic ...

BySepset Biosciences Inc.


INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

“These messages include DNA, RNA, protein and lipid biomarkers found in blood (or other biofluids) that have important applications in research, diagnosis and treatment for cancer, as well as cardiometabolic diseases like heart attack and diabetes, inflammatory diseases such as rheumatoid arthritis and Crohn’s disease, and neurodegenerative diseases ...

ByINOVIQ Ltd


Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

About the FXIa Clinical Trial Program The PACIFIC Phase IIb clinical trial program consisted of three Phase IIb studies, each one focusing on one of the following medical conditions: atrial fibrillation (irregular heartbeat), a recent non-cardioembolic ischemic stroke or a recent acute myocardial infarction (heart attack). The PACIFIC clinical trials comprised ...

ByBayer AG


Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer

Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer

“I am convinced that Elucid’s pioneering computed tomography-based technology will fundamentally shift how we treat and prevent heart disease. The company’s technology helps physicians fl ag the patients who are truly at risk for heart attacks and stroke and directs a patient-specific treatment pathway. ...

ByElucid


FAPI featured in accolades at annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting

FAPI featured in accolades at annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting

This year, the honor went to researchers at Hannover School of Medicine who demonstrated that 68Ga-FAPI-46 PET, when correlated with cardiac MRI, is a new specific indicator of active fibrosis and can identify a patient’s chance of recovery following a heart attack. The depiction of 68Ga-FAPI-46 PET signal after acute anterior myocardial infarction was ...

BySOFIE


£1.1 million project to develop new biodegradable stents

£1.1 million project to develop new biodegradable stents

Severe peripheral vascular disease (PVD) is caused by the formation of blockages in arteries, which reduces blood supply to the brain, heart, kidneys and limbs causing strokes, heart attacks, kidney failure and limb amputations. ...

ByArterius Limited


XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease

XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease

XC001 is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow. ...

ByXyloCor Therapeutics


Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

Specifically, the exquisite algorithms developed through machine learning characterize tissue types in the artery wall known to cause heart attacks, such as lipid rich necrotic core. The capability to discern complex plaque biology at the cellular and molecular level is powering new applications that can derive fractional flow reserve (FFRct), risk of ...

ByElucid


Rivaroxaban (Xarelto) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation

Rivaroxaban (Xarelto) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation

The primary efficacy endpoint was a composite of MALE and MACE, ie. acute limb ischemia, major amputation of a vascular etiology, heart attack (myocardial infarction, MI), ischemic stroke or cardiovascular death. ...

ByBayer AG


Blood ties: The inspiration behind a potential sepsis breakthrough

Blood ties: The inspiration behind a potential sepsis breakthrough

He suffered severe diarrhea and multiple heart attacks until, one by one, his organs began to shut down. Eleven days after being mistakenly diagnosed with the flu, Augustin Peña died of a little-known illness called sepsis. ...

BySepset Biosciences Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT